|
|
Countries covered: Global
The publication contains extensive profiles of leading companies including - BASF AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Cambrex Corporation, Central and Eastern Europe, China, Cipla Limited, Clariant, Degussa AG, DSM Fine Chemicals, Eastman Fine Chemicals, Kaneka, Krka D.D, Lonza Group Ltd, Merck & Company, Inc., North China Pharmaceutical Group Corporation, Pliva D.D., Ranbaxy Laboratories Limited, Roche Group, Sankyo Company, Limited, Shijiazhuang Pharmaceutical Group Co., Ltd, Sigma-Aldrich, Takeda Chemical Industries and The Rhodia Group Ltd |
More Global Regulation & Policy Reports
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity by
GBI Research
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity Summary GBI Research, the leading ...
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity by
GBI Research
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
Summary
...
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition by
Kalorama Information
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, ...
Pharmaceutical Contract Manufacturing by
Global Industry Analysts
This report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in US$ Million by the following Dosage Forms: Injectables (Injections, Vials, and IV solutions), Solid ...
Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging: Focus on Europe by
BCC Research
REPORT HIGHLIGHTS
The global pharmaceutical contract manufacturing and contract research organizations revenue reached at $196.5 billion in 2010, it will further grow to $217.9 billion ...
See all reports like this >>
Related Markets
Regulation & Policy Reports
- Drug Price Cuts in Top Five Countries of Europe - Tougher Reference Pricing Environment and Drug Price Freeze through 2013 Expected to Drive Down Healthcare Costs
- Pricing and Reimbursement in Brazil - Health Technology Assessment (HTA) Studies to Facilitate Setting of Ceiling Prices for New Drugs
- Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
- Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
- Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition